University of California San Diego School of Medicine researchers engineered sensors to detect and measure the metastatic potential of single cancer cells. Metastasis is attributed as the leading cause of death in people with cancer.
UC San Diego Medical Center in Hillcrest was named a Top Teaching Hospital by The Leapfrog Group. The award is widely acknowledged as one of the most competitive honors that a U.S. hospital can receive.
In lab and mouse experiments, UC San Diego School of Medicine researchers developed a method to leverage B cells to manufacture and secrete tumor-suppressing microRNAs.
The first in-depth look at the genome of a jellyfish reveals the origins of a successful survival strategy. Results indicate early jellyfish recycled existing genes to morph from polyp to medusa and suggest animals can radiate into new niches and forms fairly easily.
Following the FDA’s approval of chimeric antigen receptor (CAR) T-cell therapies for the treatment of certain types of non-Hodgkin lymphomas, UC San Diego Health was the first medical center in San Diego to be certified to offer this type of immunotherapy outside of a clinical trial.
A randomized clinical trial involving 97 medical centers in 20 countries, including Moores Cancer Center at UC San Diego Health, found that treating patients with head and neck cancer with the immunotherapy drug pembrolizumab is more effective and less toxic than standard chemotherapy.
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
